Maitre, Thomas
Bonnet, Maryline
Calmy, Alexandra
Raberahona, Mihaja
Rakotoarivelo, Rivonirina Andry
Rakotosamimanana, Niaina
Ambrosioni, Juan
Miró, José M.
Debeaudrap, Pierre
Muzoora, Conrad
Davis, Angharad
Meintjes, Graeme
Wasserman, Sean
Wilkinson, Robert
Eholié, Serge
Nogbou, Frédéric Ello
Calvo-Cortes, Maria-Camilla
Chazallon, Corine
Machault, Vanessa
Anglaret, Xavier
Bonnet, Fabrice http://orcid.org/0000-0001-5927-4178
Funding for this research was provided by:
EDCTP (RIA2017T-2019)
Article History
Received: 16 August 2022
Accepted: 20 September 2022
First Online: 8 November 2022
Declarations
:
: This trial received ethical approval from CNESVS (Comité National d'Ethique des Sciences de la Vie et de la Santé, Côte d'Ivoire), Comité d´Ethique de la Recherche Biomédicale, Madagascar), UNCST (Uganda National Council for Science & Technology, Uganda), University of Cap Town HREC (Human Research Ethics Committee, South Africa). Participants must provide signed and dated written informed consent prior to undergoing any study-specific procedure. For the patient with a Glasgow Coma Scale <15, the consent of a relative or a study-independent doctor is required. Deferred consent is to be obtained from the participant when their level of consciousness improves and they have the capacity to provide consent. For adolescent below the age of civil, the consent of at least one parent or legal guardian and the consent or assent of the adolescent is required
: Not applicable.
: J.M. Miro has received consulting honoraria and/or research grants from AbbVie, Angelini, Contrafect, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. F. Bonnet has received consulting honoraria and/or research grants from Gilead Sciences, Jansen, MSD, and ViiV Healthcare, outside the submitted work. The other authors have any competing interest to declare.